

Combined results from 2 programs November 17th and November 18^{th,} 2023 Live Program in Nashville, TN

Challenging Cases in Lung Cancer

Presented by Dr. Lee Schwartzberg

Program Disclosures

COIs: Consultant for Daiichi Sankyo, AstraZeneca, Seagen, Novartis, Foundation Medicine, Spectrum. Speaker for Daiichi Sankyo, Seagen, AstraZeneca, Merck

The information presented is consistent with FDA Guidelines and includes the latest clinical trial data

This program has been provided as an opportunity for discussion and learning, with insights from key opinion leaders




Lee Schwartzberg, MD Renown Oncology/Hematology Reno, Nevada

> **Cornerstone Specialty Network, LLC** Confidential – Not for Distribution



Challenging Cases in... Lung Cancer



NSCLC with HER2 alteration

What is the optimal first line therapy? Second line therapy?

Challenges with biopsy and testing?

Sequencing considerations to provide the best outcomes for patients?

Cornerstone Specialty Network, LLC



NSCLC Patient

- 65-year-old woman
- 30 pack-year smoker
- Developed back pain and worsening cough
- CT scan chest showed 3x4 cm mass in left upper lung, mediastinal LN enlargement, lytic lesion in T8 without soft tissue component
- PET scan: All above hypermetabolic
- Lesion in T12 and sacrum



Initial Diagnosis

- Tissue biopsy
- T8: NSCLC, adenocarcinoma
- TFF+
- PD-L1: CPS 30
- EGFR negative
- Not enough tissue for NGS
- ECOG PS 1

What first-line treatment do you initially recommend?

CPS=combined positive score

 $\boxed{=}$


Open-text Response Results from HCP Participants

What first-line treatment do you initially recommend?


- Chemotherapy plus immunotherapy
- Pembrolizumab + Platinum doublet
- Carbo pemetrexed pembrolizumab
- Liquid biopsy

- Carbo pemetrexed cemiplimab
- Chemo plus cemiplimab
- Get peripheral blood for NGS, then if negative treat

Cornerstone Specialty Network, LLC



1L Metastatic Treatment Options



Choice of treatment

- No head-to-head comparisons between the IO agents
- Differences in the study populations
- Differences in measurements of PD-L1

1L metastatic treatment

- Carbo/Alimta/Pembro
- 4 cycles, then maintenance Pembro/Alimta
- Partial response to therapy
- Decreased tumor size and reduced hypermetabolic after 3 cycles
- Stable for 6 more months; well tolerated except for fatigue

Progression

- CT scan shows enlargement in primary tumor and new liver mets
- MRI head negative
- ECOG PS 1
- Some increase in fatigue
- No pulmonary symptoms
- Tissue biopsy of liver lesion
- Liquid biopsy

How often do you test new metastatic lesions on first tumor recurrence (progression)?

How often do you test new metastatic lesions on first tumor recurrence (progression)?

Always

- I would at least get liquid NGS, whether a previous NGS was done or not, and if a biopsy is repeated, then I will get NGS on tissue
- At each progression
- Most of the time
- In this case I would definitely do it now. And I usually repeat at each progression to evaluate for new anomalies
- 100% liquid and tissue for first recurrence
- Liquid Bx and then decide treatment
- Send for liquid biopsy
- With liquid biopsy or if in a trial
- Most of the time if candidate for 2nd line
 - At time of each progression with liquid; will repeat tissue if >1 year
- Tissue biopsy if patient is amenable
- 100%

Cornerstone Specialty Network, LLC

Confidential – Not for Distribution

Text size indicates frequency of response



How often do you perform liquid biopsy and tissue biopsy?

- Tissue biopsy as first choice. Liquid biopsy if can't get tissue
- At diagnosis, most likely I'd get tissue + liquid; at fist progression it depends if a biopsy is repeated; at 2nd progression not always
- If the tissue Bx is easy to do.
- At initial diagnosis. Would also consider both if patient on treatment for close to a year and then progresses
- My preference is to do both
- When I see disease progression I do liquid biopsy Tissue biopsy depends case by case
- The NGS company that I use Tempus requires both
- Liquid biopsy at every progression Tissue biopsy for new site of disease if amenable and at least one year
- For all metastatic patients. Sometimes tissue is qns to do tissue testing
- At time of first diagnosis; then if tissue >1y or tumor not behaving as expected
- Tissue + liquid.
- At diagnosis of metastatic disease
- Often

Cornerstone Specialty Network, LLC

Confidential – Not for Distribution

Text size indicates frequency of response

Ē

Open-text Response Results from HCP Participants

How often do you perform a tissue biopsy if liquid biopsy is uninformative? • **100%**

- Most of the time
- Always
- Yes, at diagnosis, but not always at progression
- 75%. Sometimes patient choice or technical issues
- Frequently depending on pt PS & ease of target.
- Start second line treatment
- If locations is accessible and patient willing 100%

Cornerstone Specialty Network, LLC




How often do you test new metastatic lesions on subsequent progression? Liquid

- Liquid at every progression
- Test with liquid on each progression if PFS is >6 months
- After 2nd and 3rd
- If it's been over a year, I repeat it
- Depends on timing. Would if greater than 12 months
- Depending on timeline and if new area of spread
- Unless significant period between progressions would not test
- Sometimes liquid but rarely sequential tissue
- Think about it depending on clinical status
- Always
- Usually
- 50/50
- Often
- Not normally / not really
- Only for EGFR and ALK patients




Text size indicates frequency of response







What treatment do you recommend?




cornerstone specialty network

© 2023 Cornerstone Specialty Network. All rights reserved.

Cornerstone Specialty Network, LLC

2L Metastatic Treatment Options




Choice of treatment

- No head-to-head comparisons between the agents
- NCCN Guidelines versus FDA approved indication
- Limited data to support sequencing of therapies



Anti-HER2 agents in HER2-mutated NSCLC




Nützinger et al., Lung Cancer 186 (2023) 107385

© 2023 Cornerstone Specialty Network. All rights reserved.

cornerstone

specialty network"

NCCN Guidelines for ERBB2 (HER2) Mutated NSCLC



© 2023 Cornerstone Specialty Network. All rights reserved.

corne

Fam-Trastuzumab Deruxtecan in HER2-mutated NSCLC

DESTINY-Lung01: Multicenter, international, 2-cohort phase 2 trial

Key eligibility criteria

STUDY DESIGN

- Unresectable/metastatic nonsquamous NSCLC
- Relapsed from or is refractory to standard treatment
- Measurable disease by RECIST v1.1
- Asymptomatic CNS metastases at baseline^a
- ECOG PS of 0 or 1
- Locally reported HER2 mutation (for Cohort 2)^b

Data cutoff: May 3, 2021

- <u>91 patients with *HER2*m NSCLC were enrolled and treated with T-DXd</u>
- 15 patients (16.5%) remain on treatment to date
- 76 patients (83.5%) discontinued, primarily for progressive disease (37.4%) and adverse events (29.7%)

^aPatients with asymptomatic brain metastases not requiring ongoing steroid or anticonvulsant therapy were allowed to enroll ^bHER2 mutation documented solely from a liquid biopsy could not be used for enrolment ^cHER2 overexpression without known HER2 mutation was assessed by local assessment of archival tissue and centrally confirmed ^dPer RECIST v1.1

DCR, disease control rate; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; ICR, independent central review; IHC, immunohistochemistry; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks; RECIST v1.1, Response Evaluation Criteria in Solid Tumours version 1.1.

© 2023 Cornerstone Specialty Network. All rights reserved.

Cohort 2:Cohort 2HER2-mutatedexpansion:T-DXdHER2-mutated6.4 mg/kgT-DXdq3w6.4 mg/kgq3wN = 49

Primary end point

• Confirmed ORR by ICR^d

Secondary end points

- DOR
- PFS
- OS
- DCR
- Safety

Exploratory end point

• Biomarkers of response

Confirmed ORR, Best Overall Response and DoR

	Patients (N = 91)			
Confirmed ORR ^a , n (%)	50 (54.9) (95% CI, 44.2-65.4)			
Best overall response, n (%)				
CR	1 (1.1)			
PR	49 (53.8)			
SD	34 (37.4)			
PD	3 (3.3)			
Not evaluable	4 (4.4)			
	84 (92.3)			
DCR, n (%)	(95% CI, 84.8-96.9)			
Median DoR, months	9.3 (95% CI, 5.7-14.7)			
Median follow up, months	13.1 (range, 0.7-29.1)			

Primary endpoint


CR, complete response; DoR, duration of response; PD, progressive disease; PR, partial response; SD, stable disease.

© 2023 Cornerstone Specialty Network. All rights reserved.

ESMO Congress 2021; Abstract LBA45; NEJM 2022; 386:241-251

DESTINY-Lung01, HER2 Mutation

Best Percentage Change of Tumor Size From Baseline



^aBest change in tumor size by ICR for 85 of 91 patients for whom baseline and postbaseline data were available. Baseline is last measurement taken before enrollment. ^bThe OncomineTM Dx Target Test (Thermo Fisher Scientific) was used to confirm local HER2 mutation status and to determine HER2 amplification status. HER2 protein expression status was determined by immunohistochemistry using a modified PATHWAY anti-HER2 (4B5) (Ventana Medical Systems, Inc.) assay. Shown is best (minimum) percentage change from baseline in the sum of diameters for all target lesions; (-), negative; (+), positive; I, insertion; N, no; S, substitution; Y, yes. Blank cells (except for the prior HER2 TKI therapy row) indicate pati ents whose tumor samples were not evaluable or assessed. The upper dashed horizontal line indicates a 20% increase in tumor size in the patients who had disease progression and the lower dashed line indicates a 30% decrease in tumor size (partial response).

© 2023 Cornerstone Specialty Network. All rights reserved.

KEY DATA

DESTINY-Lung01, HER2 Mutation

Response to T-DXd in Subgroups


	No. of Responders	Confirmed ORR (95% CI)				nfirmed (95% C		
All patients	50/91	54.9 (44.2-65.4)						
HER2 mutation domain								
Kinase domain	49/85	57.6 (46.5-68.3)			-			
Prior treatment received								
Platinum-based therapy	46/86	53.5 (42.4-64.3)				-		
Platinum-based therapy and anti-PD-(L)1 therapy ^a	37/57	64.9 (51.1-77.1)						
Asymptomatic CNS metastasis at baseline ^b								
Yes	18/33	54.5 (36.4-71.9)				-	_	
No	32/58	55.2 (41.5-68.3)				-		
^a Given separately or in combination ^b Patients had asymptomatic brain metastases not requiring organize	storoid or anticonvulgant that		0%	20%	40%	60%	80%	100%

^bPatients had asymptomatic brain metastases not requiring ongoing steroid or anticonvulsant therapy

ESMO Congress 2021; Abstract LBA45; NEJM 2022; 386:241-251

DESTINY-Lung01, HER2 Mutation


Progression-free Survival



Median follow-up was 13.1 months (range, 0.7-29.1)

PFS assessed by ICR using RECIST v1.1., the median was based on Kaplan-Meier estimate, and 95% CI for median was computed using the Brookmeyer-Crowley method, and dashed lines indicate the 95% CI. Of 91 patients, 41 had progressive disease and 15 had died by the data cutoff date. Data for 35 patients were censored as indicated by tick marks; patients were censored if they discontinued treatment.

Overall Survival




Median follow-up was 13.1 months (range, 0.7-29.1 months)

Dashed lines indicate the 95% Cl. Of 91 patients, 47 had died by the data cutoff date. Data for 44 patients were censored as indicated by tick marks; patients were censored if they discontinued treatment.

KEY DATA

DESTINY-Lung02, HER2 Mutation


Best Percentage Change of Tumor Size From Baseline




<u>5.4 mg/kg T-DXd</u>		6.4 mg/kg
ORR: 49%		ORR 56%
DCR: 93%		DCR: 92%
DOR: 16.8 m		DOR NE
ILD		
Gr 1/2:	10.9%	26%
Gr 3:	1%	-
Gr 5:	1%	2%

DESTINY-Lung02, HER2 Mutation

Progression-free Survival



Overall Survival




Site of Metastases:

- Bone
- Liver
- HER2 mutation in Exon 20

Treated with famtrastuzumab deruxtecan 5.4 mg/kg Q 3 wk

Partial response (50% reduction in liver mets on CT) after 2 cycles

Grade 1 Nausea Grade 2 Neutropenia





Do you prescribe prophylactic antiemetics?

• 3 drugs

- High emetogenic regimen
- 5-HT3
- Emend zofran compazine
- 5HT3 plus dex
- Emend aloxi steroids
- Zofran, compazine alternating. If intractable, I add olanzapine
- NK-1, 5-HT3, dexamethasone
- H2b and NK-1

Cornerstone Specialty Network, LLC



EMETOGENIC POTENTIAL OF PARENTERAL ANTICANCER AGENTS

LEVEL	AGENT		
High emetic risk (>90% frequency of emesis) ^a	 AC combination defined as any chemotherapy regimen that contains an anthracycline and cyclophosphamide Carboplatin AUC ≥4 Carmustine >250 mg/m² 	 Cisplatin Cyclophosphamide >1500 mg/m² Dacarbazine Doxorubicin ≥60 mg/m² Epirubicin >90 mg/m² Fam-trastuzumab deruxtecan-nxki 	 Ifosfamide ≥2 g/m² per dose Mechlorethamine Melphalan ≥140 mg/m² Sacituzumab govitecan-hziy Streptozocin

High Emetic Risk

National

Cancer

Network[®]

NCCN

Moderate Emetic Risk

Treatment option	Treatment option	Treatment option	Treatment option	Treatment option	Treatment option
A	B	C	D	E	F
 Olanzapine NK1 receptor antagonist (RA) 5-HT3 RA Dexamethasone 	OlanzapinePalonosetronDexamethasone	NK1 RA5-HT3 RADexamethasone	5HT3-RADexamethasone	OlanzapinePalonosetronDexamethasone	 NK1 RA 5-HT3 RA Dexamethasone

All treatment options are category 1 and should be started before anticancer therapy

ENHERTU PI: moderately emetogenic – nausea occurred in 76% all grades, Grade 3-4 in 7% of patients



Metastatic Progression:

On T-DXd, has partial response to therapy for 11 months

Progression in the liver: enlarging mets and new mets

2 new bone mets on PET

ECOG remains PS 1

Some weight loss







What treatment would you recommend next?

Docetaxel / ramucirumab

• TDM-1

- Chemotherapy
- Liquid Bx, then Taxotere / ramucirumab
- Doublet vs single agent, to include a taxane
- Taxotere
- Docetaxel
- Tucatinib perhaps
- Clinical trial & antiresorptive agent
- Clinical trial or docetaxel
- Clinical trial after testing liquid Bx
- Clinical trial


Cornerstone Specialty Network, LLC

© 2023 Cornerstone Specialty Network. All rights reserved.

Confidential – Not for Distribution

Text size indicates frequency of response

3L Metastatic Treatment Options



Choice of treatment

- No head-to-head comparisons between the agents
- Differences in the study populations
- Limited data to support sequencing of anti-HER2 therapies



Program Sponsor



Cornerstone Specialty Network, LLC

